BioNTech Tumbles As Fourth-Quarter Sales Dive 65% And Miss Forecasts

BioNTech (BNTX) stock tumbled Wednesday after the Covid vaccine maker reported light fourth-quarter sales and profit, and delivered lackluster guidance for 2024.


During the December quarter, BioNTech earned $2.06 per share on just north of $1.6 billion in sales — based on today’s exchange rates. But both metrics missed Wall Street’s expectations for earnings of $2.58 a share and $1.99 billion, according to FactSet.

Sales plummeted more than 65%, while earnings crashed about 79.5% amid declining demand for Covid shots. BioNTech partners with Pfizer (PFE) on the Covid vaccine called Comirnaty. Similarly, Moderna (MRNA) and Novavax reported year-over-year sales declines for their Covid vaccines in the fourth quarter.

For the year, BioNTech, Pfizer’s partner, expects roughly $2.71 billion to $3.25 billion in sales. The high end of the company’s outlook lagged analysts’ forecast for $3.37 billion.

In premarket trades, BioNTech stock toppled 5.3% to 89.18.

More to follow.

Follow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.


Crinetics Stock Jets 19% Higher, Reversing A Three-Week Decline On Its Phase 3 Win

Fusion Rockets 99%, As Radiopharmaceuticals Space Sparks On $2 Billion AstraZeneca Takeover

Looking For The Next Big Stock Market Winners? Start With These 3 Steps

Watch IBD’s Investing Strategies Show For Actionable Market Insights

See Stocks On The List Of Leaders Near A Buy Point